GlaxoSmithKline [GLAXO] vs Senores [SENORES] Detailed Stock Comparison

GlaxoSmithKline Pharmaceuticals Ltd.

NSE
Loading...

Senores Pharmaceuticals Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: GlaxoSmithKline Pharmaceuticals Ltd. wins in 11 metrics, Senores Pharmaceuticals Ltd. wins in 7 metrics, with 0 ties. GlaxoSmithKline Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric GlaxoSmithKline Pharmaceuticals Ltd. Senores Pharmaceuticals Ltd. Better
P/E Ratio (TTM) 41.55 35.50 Senores Pharmaceuticals Ltd.
Price-to-Book Ratio 24.80 5.54 Senores Pharmaceuticals Ltd.
Debt-to-Equity Ratio 2.09 28.90 GlaxoSmithKline Pharmaceuticals Ltd.
PEG Ratio 2.44 0.80 Senores Pharmaceuticals Ltd.
EV/EBITDA 31.46 26.45 Senores Pharmaceuticals Ltd.
Profit Margin (TTM) 26.86% 18.36% GlaxoSmithKline Pharmaceuticals Ltd.
Operating Margin (TTM) 33.71% 27.99% GlaxoSmithKline Pharmaceuticals Ltd.
EBITDA Margin (TTM) 33.71% 27.99% GlaxoSmithKline Pharmaceuticals Ltd.
Return on Equity 47.54% 7.21% GlaxoSmithKline Pharmaceuticals Ltd.
Return on Assets (TTM) 22.58% 4.77% GlaxoSmithKline Pharmaceuticals Ltd.
Free Cash Flow (TTM) $12.65B $-2.03B GlaxoSmithKline Pharmaceuticals Ltd.
Dividend Yield 1.65% N/A N/A
1-Year Return -35.63% 131.62% Senores Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 11.14 7.59 Senores Pharmaceuticals Ltd.
Enterprise Value $397.44B $39.72B GlaxoSmithKline Pharmaceuticals Ltd.
EV/Revenue Ratio 10.46 7.18 Senores Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 65.06% 59.34% GlaxoSmithKline Pharmaceuticals Ltd.
Revenue per Share (TTM) $224 $122 GlaxoSmithKline Pharmaceuticals Ltd.
Earnings per Share (Diluted) $60.16 $25.68 GlaxoSmithKline Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.10 N/A N/A

GlaxoSmithKline Pharmaceuticals Ltd. vs Senores Pharmaceuticals Ltd. Stock Performance Analysis

Loading Price Chart...

GLAXO
SENORES

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
GlaxoSmithKline Pharmaceuticals Ltd.-0.31%-3.19%-13.28%-11.99%-17.96%-13.88%
Senores Pharmaceuticals Ltd.-0.53%27.43%22.17%72.40%57.40%55.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
GlaxoSmithKline Pharmaceuticals Ltd.-35.63%50.14%45.44%-39.87%-9.78%324.98%
Senores Pharmaceuticals Ltd.131.62%125.07%125.07%125.07%125.07%125.07%

Performance & Financial Health Analysis: GlaxoSmithKline Pharmaceuticals Ltd. vs Senores Pharmaceuticals Ltd.

MetricGLAXOSENORES
Market Information
Market Cap i₹422.67B₹41.04B
Market Cap CategoryLarge capSmall cap
10 Day Avg. Volume i42,008296,447
90 Day Avg. Volume i51,960217,213
Last Close₹2,115.00₹1,283.20
52 Week Range₹2,088.10 - ₹3,500.00₹513.00 - ₹1,311.00
% from 52W High-39.57%-2.12%
All-Time High₹3,872.00 (Mar 28, 2016)₹1,311.00 (Jun 15, 2026)
% from All-Time High-45.38%-2.12%
Growth Metrics
Quarterly Revenue Growth0.10%0.60%
Quarterly Earnings Growth0.29%0.84%
Financial Health
Profit Margin (TTM) i0.27%0.18%
Operating Margin (TTM) i0.34%0.28%
Return on Equity (TTM) i0.48%0.07%
Debt to Equity (MRQ) i2.0928.90
Cash & Liquidity
Book Value per Share (MRQ)₹100.81₹164.41
Cash per Share (MRQ)₹121.65₹46.65
Operating Cash Flow (TTM) i₹12.73B₹-71,800,000
Levered Free Cash Flow (TTM) i₹9.28B₹585.60M
Dividends
Last 12-Month Dividend Yield i1.65%N/A
Last 12-Month Dividend i₹54.00N/A

Valuation & Enterprise Metrics Analysis: GlaxoSmithKline Pharmaceuticals Ltd. vs Senores Pharmaceuticals Ltd.

MetricGLAXO (Apr 24, 2026)SENORES (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i41.5535.50
Forward P/E i36.4629.38
PEG Ratio i2.440.80
Price to Sales (TTM) i11.147.59
Price to Book (MRQ) i24.805.54
Market Capitalization
Market Capitalization i₹422.67B₹41.04B
Enterprise Value i₹397.44B₹39.72B
Enterprise Value Metrics
Enterprise to Revenue i10.467.18
Enterprise to EBITDA i31.4626.45
Risk & Other Metrics
Beta i0.10N/A
Book Value per Share (MRQ) i₹100.81₹164.41

Financial Statements Comparison: GlaxoSmithKline Pharmaceuticals Ltd. vs Senores Pharmaceuticals Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLAXO (2025)SENORES (2025)
Revenue/Sales i37.26B3.83B
Cost of Goods Sold i14.73B1.90B
COGS % of Revenue i39.5%49.6%
Gross Profit i22.53B1.93B
Gross Margin i60.5%50.4%
Research & Development iN/A50.60M
Operating Income (EBIT) i11.14B728.10M
Operating Margin i29.9%19.0%
EBITDA i12.55B1.08B
EBITDA Margin i33.7%28.2%
Pre-Tax Income i12.60B705.70M
Pre-Tax Income % of Revenue i33.8%18.4%
Income Tax i3.32B122.30M
Income Tax % of Revenue i8.9%3.2%
Net Income (Profit) i9.28B583.40M
Profit Margin i24.9%15.2%

Balance Sheet & Liquidity Metrics

MetricGLAXO (2025)SENORES (2025)
Cash & Equivalents i5.39B1.05B
Total Current Assets i34.10B7.22B
Total Current Assets % of Revenue i91.5%188.7%
Total Current Liabilities i19.05B2.41B
Total Current Liabilities % of Revenue i51.1%62.9%
Long-Term Debt i24.92M1.71B
Long-Term Debt % of Revenue i0.1%44.6%
Total Shareholders Equity i19.51B8.12B
Retained Earnings i10.59B899.10M
Retained Earnings % of Revenue i28.4%23.5%
Property, Plant & Equipment i2.70B64.00M

Cash Flow Statement Comparison

MetricGLAXO (2025)SENORES (2025)
Operating Cash Flow i12.73B-71.80M
Operating Cash Flow % of Revenue i34.2%-1.9%
Capital Expenditures i-190.05M-1.58B
Free Cash Flow i12.65B-2.03B
FCF Margin i34.0%-53.1%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLAXOSENORES
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i169.41M46.05M
Float Shares i41.25M18.34M
% Held by Insiders i75.65%55.57%
% Held by Institutions i7.47%7.74%
% Held by Public i16.88%36.69%

Dividend Analysis & Yield Comparison: GlaxoSmithKline Pharmaceuticals Ltd. vs Senores Pharmaceuticals Ltd.

MetricGLAXOSENORES
Last 12-Month Dividend i₹54.00N/A
Last 12-Month Dividend Yield i1.65%N/A
3-Year Avg Annual Dividend i₹59.33N/A
3-Year Avg Dividend Yield i1.86%N/A
3-Year Total Dividends i₹178.00N/A
Ex-Dividend DateMay 30, 2025N/A